Affymax Inc.
Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.
Affymax Inc. (AFFY) - Net Assets
Latest net assets as of June 2014: $5.17 Million USD
Based on the latest financial reports, Affymax Inc. (AFFY) has net assets worth $5.17 Million USD as of June 2014.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.38 Million) and total liabilities ($214.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.17 Million |
| % of Total Assets | 96.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | -102.13% |
| 10-Year Change | N/A |
| Growth Volatility | 247.92 |
Affymax Inc. - Net Assets Trend (2004–2013)
This chart illustrates how Affymax Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Affymax Inc. (2004–2013)
The table below shows the annual net assets of Affymax Inc. from 2004 to 2013.
| Year | Net Assets | Change |
|---|---|---|
| 2013-12-31 | $-1.43 Million | -117.24% |
| 2012-12-31 | $8.28 Million | -89.10% |
| 2011-12-31 | $76.00 Million | +4.76% |
| 2010-12-31 | $72.55 Million | +8.43% |
| 2009-12-31 | $66.91 Million | +644.71% |
| 2008-12-31 | $8.98 Million | -89.33% |
| 2007-12-31 | $84.19 Million | -27.98% |
| 2006-12-31 | $116.90 Million | +202.82% |
| 2005-12-31 | $-113.69 Million | -30.44% |
| 2004-12-31 | $-87.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Affymax Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 54789300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2013)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | % |
| Other Components | $556.67 Million | % |
| Total Equity | $-1.43 Million | 100.00% |
Affymax Inc. Competitors by Market Cap
The table below lists competitors of Affymax Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bakrieland Development Tbk
JK:ELTY
|
$23.70 |
|
HYDROTEC
BE:HYW
|
$23.94 |
|
STRATEX INTL (S1Y.SG)
STU:S1Y
|
$24.00 |
|
Zann Corp
PINK:ZNNC
|
$24.29 |
|
Unlimit Group A/S
CO:UNLGRP
|
$23.39 |
|
Liberty Metals Ltd
AU:LIB
|
$23.28 |
|
PH Resorts Group Holdings Inc
PSE:PHR
|
$22.98 |
|
Trio Resources Inc
PINK:TRII
|
$22.73 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Affymax Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2012 to 2013, total equity changed from 8,281,000 to -1,428,000, a change of -9,709,000 (-117.2%).
- Net loss of 14,424,000 reduced equity.
- Share repurchases of 271,000 reduced equity.
- Other comprehensive income increased equity by 2,000.
- Other factors increased equity by 4,984,000.
Equity Change Factors (2012 to 2013)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.42 Million | -1010.08% |
| Share Repurchases | $271.00K | -18.98% |
| Other Comprehensive Income | $2.00K | +0.14% |
| Other Changes | $4.98 Million | +349.02% |
| Total Change | $- | -117.24% |
Book Value vs Market Value Analysis
This analysis compares Affymax Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $-38.70 | $0.00 | x |
| 2002-12-31 | $-139.63 | $0.00 | x |
| 2004-12-31 | $-285.78 | $0.00 | x |
| 2005-12-31 | $-348.75 | $0.00 | x |
| 2006-12-31 | $77.52 | $0.00 | x |
| 2007-12-31 | $5.63 | $0.00 | x |
| 2008-12-31 | $0.59 | $0.00 | x |
| 2009-12-31 | $3.55 | $0.00 | x |
| 2010-12-31 | $2.96 | $0.00 | x |
| 2011-12-31 | $2.28 | $0.00 | x |
| 2012-12-31 | $0.23 | $0.00 | x |
| 2013-12-31 | $-0.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Affymax Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1053.62%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-199.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.33 Million |
| 2002 | 0.00% | -27229.13% | 0.00x | 0.00x | $-24.32 Million |
| 2004 | 0.00% | -14170.86% | 0.01x | 0.00x | $-12.68 Million |
| 2005 | 0.00% | -44021.62% | 0.00x | 0.00x | $-21.21 Million |
| 2006 | -41.31% | -411.80% | 0.05x | 2.14x | $-59.98 Million |
| 2007 | -51.16% | -97.14% | 0.20x | 2.68x | $-51.49 Million |
| 2008 | -962.93% | -104.42% | 0.49x | 18.67x | $-87.41 Million |
| 2009 | -114.39% | -66.61% | 0.54x | 3.16x | $-83.22 Million |
| 2010 | -19.40% | -12.51% | 0.86x | 1.81x | $-21.33 Million |
| 2011 | -80.75% | -128.60% | 0.40x | 1.57x | $-68.97 Million |
| 2012 | -1128.03% | -98.98% | 0.80x | 14.28x | $-94.24 Million |
| 2013 | 0.00% | -1053.62% | 0.18x | 0.00x | $-14.28 Million |
Industry Comparison
This section compares Affymax Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Affymax Inc. (AFFY) | $5.17 Million | 0.00% | 0.04x | $23.47 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |